Blue Water Ventures International, Inc. Stock

Equities

BWVI

US09609E1055

Biotechnology & Medical Research

Market Closed - OTC Markets 03:30:42 2024-04-24 pm EDT 5-day change 1st Jan Change
0.014 USD +2.19% Intraday chart for Blue Water Ventures International, Inc. -6.67% -77.42%
Dynamic Chart
Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes CI
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman CI
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding CI
Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder CI
Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD CI
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD CI
Blue Water Ventures International, Inc. announced a financing transaction CI
Blue Water Ventures International, Inc. announced that it has received $0.771 million in funding CI
Blue Water Ventures International, Inc. announced that it expects to receive $0.771 million in funding CI
Blue Water Ventures International, Inc. completed the acquisition of Psycheceutical, Inc. CI
Blue Water Ventures International, Inc. signed a non-binding letter of intent to acquire Psycheceutical, Inc. CI
Blue Water Ventures International Signs Extension on Pulaski Recovery CI
Blue Water Ventures International, Inc. and Project Partner Endurance Exploration Group, Inc. Announce Preparations for 2019 Operations CI
Blue Water Ventures International, Inc. Announces the Launch of its Internationally Branded Line of Jewelry with Canada’s SponsorsOne, Inc. and Sponsors One Media, Inc CI
Blue Water Ventures International, Inc. Signs Brand Development Agreement with SponsorsOne Inc CI
More news
1 day+2.19%
1 week-6.67%
Current month-30.00%
1 month-42.39%
3 months-72.22%
6 months-86.00%
Current year-77.42%
More quotes
1 week
0.01
Extreme 0.0122
0.02
1 month
0.01
Extreme 0.0121
0.02
Current year
0.01
Extreme 0.011
0.08
1 year
0.01
Extreme 0.011
0.19
3 years
0.01
Extreme 0.011
0.75
5 years
0.01
Extreme 0.0103
0.75
10 years
0.01
Extreme 0.0103
0.75
More quotes
Managers TitleAgeSince
Chief Executive Officer - Dec. 11
Director of Finance/CFO 70 -
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 74 -
Director/Board Member - -
Director of Finance/CFO 70 -
More insiders
Psycheceutical Bioscience, Inc. is a bioscience company. The Company is engaged in developing cutting-edge delivery technologies to support safe psychedelic pharmaceutical medicines. The Company's technology is intended to deliver compounds across the blood-brain barrier while bypassing the gastrointestinal (GI) tract and liver, eliminating hallucinogenic effects and vastly reducing exposure to drug toxicities and side effects. The Company's systematic delivery system is designed to use extremely small multi-layered compounds, called Janus particles, to deliver targeted doses of any psychedelic compound directly through the blood-brain barrier, thereby bypassing the liver and reducing toxicity and side effects. The Company's NeuroDirect topical delivery system is a non-systemic delivery technology designed to deliver neuro-active compounds directly into the nerve tissue through topical application at the back of the neck.
More about the company